Cryoglobulinemia is a clinical condition characterised by the presence of circulating globulins that precipitate at a temperature lower than 37°C and re-dissolve with warming. We can distinguish 3 different types of cryoglobulinemia, according to their immunochemical characteristics. Cryoglobulinemia can be associated with infectious, inflammatory or neoplastic diseases. Cryoglobulinemia type II can be associated with chronic HCV-hepatitis. Clinically, cryoglobulinemias cause hyperviscosity-related symptoms or lesions by immunocomplex deposition (cryoglobulinemic vasculitis). Many organs and systems can be involved, from the skin to the joints, from the central nervous system to the kidney. Diagnosis requires a careful clinical and physical evaluation and the demonstration of circulating cryoglobulins by cryoprecipitation and immunoelectrophoresis. The therapeutic goals are the treatment of the underlying diseases and the complication and prevention of progression/relapse. It is obvious that this disorder can involve different specialists, but the internist plays a central role: heidentifies the disease and the associated condition, he treats the underlying disorder and refers the patient to the specialists for the organ-specific manifestations.
The term Cryoglobulinaemia (C.) identifies a clinical condition characterised by the presence of circulating globulins which precipitate as serum is cooled below core body temperatures and redissolve with warming (l ). The first description of cryoglobulinaemia goes back to Wintrope and Buell in 1933; they described acaseof"extraordinary hyperproteinaemia" in a patient affected by multiple myeloma (2) . Melzer and Franklin subsequently correlated cryoglobulinaemia with purpura, arthralgias andfatigue (Meltzer's and Franklin's triad) (3) . The discovery of the relationship between cryoglobulinaemia and hepatitis C virus infection (HCV) was another important step (4) (5) . Before HCV, the pathogenetic role of hepatitis B virus (HBV) had often been emphasised because of liver involvement in mixed cryoglobulinaemia; however, several scientists, especially Italians, had already hypothesised a different aetiopathogenesis (6) .
Liver involvement in patients affected by cryoglobulinaemia has always been a critical factor in the understanding of this disease; several authors agree on decreased reticuloendothelial function as a factor that may favour immunocomplex deposition (7) . The formation of cryoglobulins can be induced by secondary immunological changes due to liver dysfunction (8) . This hypothesis is supported by the presence, within the intra-hepatic lymphatic aggregates observed in HCV-related chronic liver disease, of polyclonal B-cells in patients affected by cryoglobulinaemia type III and monoclonal B-cells in cryoglobulinaemia type II.
Cryoglobulinaemia can be associated with infectious, inflammatory or neoplastic disease. The immunochemical classification, proposed by Brouet in 1974, is still valid. We can distinguish 3 types of cryoglobulinaemia (9) . C. type I is characterised by only one monoclonal immunoglobulin (IgM, less frequently IgG), due to the malignant proliferation of a B-cell clone, without rheumatoid factor (RF) activity. C. type I occurs, typically, in association with Iymphoproliferative and myelodisplastic disorders, multiple myeloma, and Waldenstrom's macroglobulinemia. C. type II and III are defined as "mixed" (MC): they are characterised by two different isotypes. In c. type II there is a polyclonal and a monoclonal isotype (usually IgM k with rheumatoid activity). In type III the isotypes are both polyclonal, (IgG and IgM with RF activity); in type II and III, there is a prolonged stimulation of the immune system with subsequent B-cell proliferation. RF, present in autoimmune and Iymphoprol iferative disorders, captures, processes and presents the antigens enclosed in irnmunocomplexes to T-cells (10) . The mechanism of cryoprecipitation, in this case, seems to be linked just to the RF, with the subsequent formation of immunocomplexes, enhanced by acute phase reactants (i.e. fibronectin).
The cryoprecipitate in type II is due to IgMk with RF-and anti-idiotype-activity. In mixed cryoglobulinaemias (MC), the immunocomplexes (mono-and polyclonal IgM with rheumatoid factor activity) lead to complement activation. In c. type II, it was hypothesised that, at low body temperatures, IgM RF-IgG complexes, present already at 37°C, increase the number of links available on RF complex; there would thus be the formation of complexes of such size that the favourable interactions for solubilization is exceeded (I I). An altered macrophagic clearance also reduces immunocomplex clearance and leads to immunocomplex accumulation in the walls of small vessels and sometimes, in larger vessels too, with damage to various organs and systems.
Clinical conditions associated with c. type II are chronic hepatitis HCY-related, macroglobulinemia and Sjogren's syndrome (11) (12) . C. type III is associated with viral, bacterial and parasitic infections (HCY infection included), autoimmune and neoplastic diseases (4). As cryoglobulinaernias can affect different organs, it is clear that they can involve many specialists, but we believe that their correct evaluation requires an internist. The internist plays a central role: he identifies the disease, the type and the associated condition, treats the underlying disease and, lastly, refers the patient to the specialists for the organspecific manifestations.
CRYOGLOBULINAEMIA AND HCY HEPATITIS
The identification of HCY led to a better definition of "non-A, non-B" hepatitis and explained the liver involvement in patients with cryoglobulinemia but without HBY. The presence of HCY focused the attention on the Iymphoproliferative nature of the process leading to monoclonal RF production. In our opinion, HCY infection is no longer an exclusive gastroenterological condition (13) (14) . In the acute phase of an HCY infection, increased IgM levels reflect the response of the immune system to different viral stimuli. During the chronic phase, however, the eventual increase of IgM is due to a production of antibodies (auto-antibodies and/or antibodies against Fe fragment ofIgG, RF). Some of these immunoglobulins form cryoprecipitable immunocomplexes, causing cryoglobulinaemia type II (monoclonal IgM) or type III (polyclonal IgM).
The close association between HCY and cryoglobulinaemia is supported by three basic data (II):
I. the amount of HCY-RNA included in the cryoprecipitate is 10 to 1000 times greater than the amount in the supernatant.
2. the evaluation of soluble and cryoprecipitable immunocomplexes suggests that the IgM-RF component links to IgG against HCY proteins.
3. viral proteins are expressed in the skin of patients with cryoglobulinaemic vasculitis and in the kidney of patients with cryoglobulinaemia and mernbrano-proliferative glomerulonephritis.
An analysis of cryoglobulin compounds showed the presence of virions, IgG against HCY and RF. In particular, IgM RF have the same cross-idiotype "WA Xld" which suggests that HCY causes the production of IgM RF W A (15) (16) .
The prevalence of cryoglobulinaemia is particularly high in patients affected by HCYrelated hepatitis (54.3%) compared with other viral hepatitides (HBY: 15%, others 32%) (17) (18) . Antibodies against HCY and/or Hey RNA are found in about 50-80% of patients affected by cryoglobulinaemia, while the presence of cryoglobulins in patients affected by HCY is variable (a high prevalence in the Mediterranean area; peaks of 50-90% in Italy and France). Such variability may be due to a lack of procedure standardisation; more sensitive procedures, such as immuno-electrofixation or Western blot are required (19) .
Cryoglobulinaemiacorrelates with the duration of the disease and the presence of cirrhosis, (20) but not with the viral genotype (21) . According to a recent study, the phenotype DR 11 is associated with an increased risk of c. type II in patients with chronic HCV infection. The phenotype HLA-DR7, instead, seems to have a protective role. This finding supports the central role played by immunogenetic predisposition (22) . Ethnic differences, as in Italy and Japan, are likely to be involved in B-cell proliferation underlying the pathogenesis of the cryoglobulinaemia (23 ) .
The presence of viral RNA in blood cells and mononuclear cells of bone marrow does not only represents a viral reservoir that prolongs viral persistence (24) (25) . The close association between HCV infection, c. type II and non-Hodgkin lymphomas suggests the pathogenetic role ofHCV in lymphoproliferation. In some cases of c. type II, there could be a progression toward a B-cell lymphoma (7, 11, 26) . Today, the mechanisms by which HCV induces this proliferation and the reason for which not all patients with HCV infection develop cryioglobulinemia are still obscure.
According to the current hypothesis, firstly, a phase of immune response against HCV occurs (IgM-WA without RF; they do not precipitate or cause vasculitis); a prolonged stimulus then causes the expansion of oligoclonal foci or even a selection of monoclonal IgM-W A (11).
CRYOGLOBULINAEMIA, HCV AND LYMPHOMA GENESIS
It is well-known that HCV is a hepatotropic and lymphotropic virus: active or latent viral replication in peripheral lymphocytes of patients affected by HCV-related hepatitis (27) . The infection of lymphoid tissue could represent a reservoir; furthermore, the quasispecies nature ofHCV allows it to escape immune surveillance and favours the persistence of infection in the host (28) . These biologic characteristics can explain the appearance ofautoimmune and 1ymphoproIiferati ve disorders in patients affected by HCV (29) . A probable causal relation between hepatotropic virus and malignant lymphomas has been hypothesised since the 1970s (30) . In 1994, HCV infection was demonstrated for the first time in a large number ofItalian patients with non-Hodgkin, non-selected, B-celllymphomas (BCL), (31) . These associations were confirmed in patients with BCL from different countries (29) . An additional clue of a possible direct role of HCV in lymphoma-genesis was provided by researchers who showed HCV-related proteins and/or mainly intermediate, HCV replicative particles, in peripheral lymphocytes and histologic samples of patients affected by lymphoma (28, 32) . However, the role of HCV in lymphomagenesis is still controversial. First of all, there is a wide geographic variability in the incidence of HCV infection in patients with BCL (North-southern gradient in Europe; differences between southern California, mainly populated with Hispanics, and Western USA) (28, (31) (32) 34) . As HCV infection prevalence in Westerncountries is homogeneous, this variability suggests that HCV alone could not be enough to produce lymphoma, and that genetic and environmental co-factors may be necessary to cause a malignancy (28) .
In the second place, HCV is a single chain RNA virus, without an intermediate DNA in its replication, so that its genomic sequences are not integrated in host genoma. It has been proposed that HCV infection has a chronic stimulating effect on the immune system that favours the development and the selection of abnormal clones (28) . Patients with type II MC develop a B-cell lymphoma, usually after a long course (34) . This complication may be correlated with the expansion ofperipheral B-cells and with lymphoid infiltrates in the liver and bone marrow of patients with MC (35) . In particular, these infiltrates have been considered as "early lymphomas", as they include lymphoid elements indistinguishable from those of B-cel1 lymphoma/chronic leukaemia (B-CLLlBCL) and from immunocytoma (Ic) (36) . However, apart from malignant, lymphomas, they usually remain unchanged for years and are followed by lymphoid malignancies only in 10% of the cases (37) . These characteristics justify the term, recently suggested, of "monotypic lymphoproliferative disorder of undetermined significance (MLDUS)" (37) . Type II MC-related MLDUS has the highest incidence in the same geographic area where about 30% of patients affected by "idiopathic" BCL also show antibodies against HCY and where an increased prevalence ofHCY genotype 2a/c has been observed either in MC either in BCL (20) . MC type IIrelated MLDUS has two main pathologic patterns; specificaIly, B-CLL and Ic.
Lymphoid infiltrate of MLDUS type B-CLL observed in needle-biopsies of liver and bone marrow are characterised by a mixture of smaIl lymphocytes, pro-lymphocytes, and paraimmunoblastic ceIls. Repeated biopsies do not generaIly show any expansion of these ceIls; they can also go to histologic regression in the case of cirrhotic progression (37) . Further, patients with MLDUS, who received repeated bone marrow biopsies before and after interferon administration, showed a regression of the infiltrates in association with the viral clearance (32) . Only a few molecular studies have been conducted. Magalini et aI, firstly, reported the micro-dissection with PCR of B-ceIIular component in 35 lymphoid portal infiltrates of I I patients with HCY infection (7 with MC type II) (37); they analysed the H region of Ig and demonstrated that, in spite of the monotypic pattern observed by immunohistochemistry, the Iymphoproliferation is due to more than one B clone.
In spite of the morphology and monotypic expression oflight chains ofIg, Iymphoproliferation that occurs in patients affected by HCY and MC type II cannot be considered as a true lymphoma because: (a) it is usually characterised by oligoclonality, and (b) malignant lymphomas arise from a B clone different to the one causing MLDUS. In 1997 the translocation t(l4; I8) was identified in peripheral lymphocytes in patients affected by HCY (38) . Further, a significantly high percentage of recombination and overexpression of Bcl2 was demonstrated both in HCY hepatitis (26%) and in HCY-related MC type II (7 1%) versus HCY -nonrelated chronic hepatitis (4%). Translocation t(l4; I8) correlates with the presence of HCY genotype 2c (39) .
HCY-related Iymphoproliferation is a multifactorial process with various steps, so multiple genetic aberrations are likely required.
Prolonged survival may expose B-ceIIs to other genetic aberrations, leading to malignant lymphoma. The oncogenic role of HCY in hepatoceIlular carcinoma development is weIlknown, regardless of cirrhotic progression (40); the virus could also be invol ved in other malignancies (i.e. thyroid ones) (41) . Although limited to MC and some cases of "idiopathic" BCL (20-30%), HCY-related Iymphomagenesis has a high pathogenetic value. In fact, monotypic/oligoclonal Iymphoproliferation could emerge in the setting of inflammatory response to HCY, because of the (virus-related?) translocation t( 14; 18) that favours the proliferation of some clones out of others by inhibition of the apoptosis (42) . These clones require the persistence of HCY direct antigenic stimulus (43) (44) and T-ceIl cooperation to preserve them; appropriate treatments can thus induce both viral clearance and MLDUS regression (45) . Chronic stimulation of B-ceIls due to HCY infection and its possible concomitant autoimmune phenomena, along with the onset of this clonal selection, represents the favourable milieu for the development of a mal ignant lymphoma. HCY -related Iymphoproliferation in patients with MC type II thus has similarities with the Iymphomagenesis model in patients with HIY or Helicobacterpy lorirelated gastritis (46) . The development of lymphomas in patients with HCY infection without MC type II naturaIly requires further molecular studies.
CLINICAL FEATURES
Cryoglobulinaemia type I is more likely to be symptomatic and usually associated with acrocyanosis, mucosal or retinal haemorrhagias, Raynaud's phenomenon and arterial thrombosis; high levels of type I cryoglobulins are associated with hyperviscosity-related symptoms. Mixed Cryog lob ulin aemias are less frequently symptomatic, and are usuaIly associated with purpura and arthralgias/arthritis due to tissue deposition of immunocomplexes.
Cryoglobulinaemia type I
The clinical picture is characterised essentiaIIy by hyperviscosity-related symptoms and the symptoms and signs of the underlying disease (myeloma, POEMS).
Hyperviscosity syndrome includes mucosal bleeding, retinal haemorrhages, arterial thrombosis; retinal central vein occlusion is also common. Confusion appears also with slight increases of viscosity; headache, dizziness, nystagmus, hypoacusia or deafness and visual alterations due to retinal venous congestion or haemorrhages may also be present; more severe disorders include bleeding, congestive heart disease and renal failure (48) . Laboratory findings, pseudohyponatremia and pseudohypoglycemia indirectly confirm the hyperviscosity. Schnitzler's syndrome is characterised by non-itching, urticarial lesions, together with periodic fever, bone pain and Iymphoadenopaty associated with increased monoclonal IgM (>1000 mg per dl) (47) . The Sia test, at the the patient's bedside, is a screening procedure for hyperviscosity. A white filamentous precipitate, produced by putting a serum drop into a cylinder of distilled water, denotes the need for hyperviscosity measuring. The Sia test is often positive in the case of paraproteinaemia IgM; on the contrary, it is less frequently positive in the case of paraproteinaemia IgG.
Mixed Cryoglobulinaemia (MC)
The so-called Cryoglobulinaemic Syndrome is characterised by the organ-specific disorders induced by cryoglobulins (purpura, arthralgias, nephropathy and neuropathy) and by noncryoglobulin-related organ damage (liver involvement and Iymphoproliferation)
The Franklin-Meltzer triad represents one of the probable clinical pictures. The main symptoms and signs are linked with immunocomplex vasculitis (purpura, arthralgias, glomerulonephritis and neuropathy). Dysprotidaemic purpura is the main clinical sign, and often the first, or the only clue of the disease in the absence of renal or peripheral nervous involvement.
Cryoglobulinaemic vasculits. This is inversely linked with cryocrit, perhaps because of the intrinsic capability of immunocomplexes to activate the complement in situ.
In a series of over than 200 patients, Dammacco et al. recently reported that purpura is the most frequent manifestation (90% of the cases) (11) . It is due to a leukocytoclastic vasculitis involving capillaries and post-capillary venules of superficial derma and, in some cases subcutaneous vessels. Histologically, neutrophilic infiltrates, endothelial swelling and haemorrhages are observed during the active phase (47) . Intermittent, palpable, nonitching lesions, usually preceded by paresthesias, have a "sock" distribution, but they can sometimes affect the thigh or, rarely, the trunk. The intermittence of the purpuric rashes (relapsing poussee last 3-10 days), cause the classic ochreous metachromasia, due to the haemosiderin deposition. Typically, it differs from infectious and thrombocytopenic purpura merely by the presence of infiltrated and palpable haemorrhages with marked polymorphism and the probable dystrophic lesions. The degree of purpura correlates with the severity of the disease. The GISC study (Italian Group for Cryoglobulinaemia study) classifies the diseases according to the proximal extent of the lesions (51) . Sometimes there are malleolar ulcers, that express a higher severity of the disease with some morphologic aspects similar to those of venous failure. The onset can be expressed, especially in females, by Raynaud's phenomenon (usually in absence of trophic alterations), or by acrocyanosis, probably due to a particular sensitivity to cold and/or vasoconstrictor stimuli associated with immunocomplex microvascular damage.
Articular involvement. This is common; typical symptoms are transient arthralgias with poor inflammatory signs and morning stiffness (51) of large joints but also of proximal interphalangeal and metacarpo-phalangeal joints. Fibromyalgiaorpolymyalgia-like pictures are also possible (51) .
Cryoglobulinemic nephropathy. Acute nephritis (haematuria and proteinuria) or nephrotic syndrome appears late, preceded by long-lasting proteinuria and microhaematuria. Chronic renal failure and uraemia are rare, but they indicate a bad prognosis. Systemic arterial hypertension is a further adverse factor. Histologically, a mernbrano-proliferative glomerulonephritis with huge endocapillary proliferation, glomerular thrombosis with IgG-IgM deposition and inflammatory infiltrates into the wall of small and medium vessels with necrosis (11, 51) is observed. Similar findings can be found in other organs such as skin, bowel, liver and lung.
Neurological damage. This can be caused by different mechanisms i.e. immuno-mediated demyelinization (anti-Myelin Associated Glycoprotein has been observed in cryoglobulinaemia type I), vasa nervorum occlusion or epineural vasculitis with subsequent ischemic damage ofaxons. The peripheral nervous system is mainly affected, with a typical picture of sensitivemotor neuropathy (paresthesia, painful dysesthesia, muscular fatigue, sense of burning and "pin-prick" like pain in the legs, the ankles and the feet).
Physical examination shows the movements of dorsal flexion and abduction of the feet to be impaired; patellar and achilleus osteotendinous reflexes are sluggish (51) . The central nervous system can sometimes be involved, with transient dysarthria and hemiplegia (52) . In patients also affected by HCV hepatitis, liver involvement and neuropathy seem more severe if compared with what is observed in patients without HCV infection (53) . Rarely, there may be lung involvement, recurrent abdominal pain and coronary vasculitis (51) . When the liver is involved, histologic examination shows microsteatosis, lymphoid portal aggregates, hyperplasia of sinusoidal cells, intralobular foci of lymphomonocytic aggregates with rare intralobular necrosis and, less frequently, signs of active chronic hepatitis, with or without cirrhosis.
DIAGNOSIS
Purpura is not always the first manifestation, so its absence does not exclude the disease. At present, there are no well-assessed diagnostic criteria, although in 1989 the GISC suggested major and minor criteria for MC diagnosis. A careful clinical history that evaluates the different clinical pictures is essential; in particular, symptoms and signs of chronic hepatitis should be investigated to understand the cause and assess the presence or the absence ofHCV. It is also important to exclude the other causes of dysprotidaemic purpuras and dyschromic drug-related lesions.
To detect cryoglobulins, the blood should be drawn with a warmed syringe; it should coagulate at the same temperature. The serum, obtained by centrifugation, should subsequently be kept at +2 /+4°C for at least 48 hours. The cryoglobulins precipitate at the bottom of the tube; washing with saline solution, buffered cold, makes it possible to separate the other serum proteins. By centrifugation in a Wintrobe's tube, we can obtain the cryocrit which is the volume, percent of the precipitate compared with the total volume of serum. The subsequent step is the identification of the type by immunoelectrophoresis (11) . More sensitive methods than immunoelectrophoresis, immunoelectrofixation or Western blot may be necessary for the diagnosis (20) .
The complement concentration is reduced and C4 is undetectable in some cases. Some IgM can show an activity against the complement. The RF can be positive; similarly, in mixed cryoglobulinaemia the Waaler-Rose's reaction could be positive.
In conclusion, if cryoglobulins are present, it is essential to diagnose the underlying disease, in primis, HCV-infection. In the presence ofantibodies against HCV, along with the assessment of the liver damage, qualitative analysis and genotypic characterisation are necessary for prognosis evaluation.
THERAPY
The therapeutic goals are to treat the underlying disease, to prevent the progression and to control the relapses. Some simple changes oflife-styIe are required such as reducing exposure to cold, protecting the extremities from the cold, avoiding intensive physical exercise and reducing orthostatism and other long-lasting positions. In c. type I, the treatment must deal with malignant lymphoproliferation (multiple myeloma, Waldenstrorns disease) with alchilants and prednisone. In the presence of hyperviscosity syndrome, plasma-exchange is the best treatment. Because of its characteristics, the treatment ofMC is more difficu It. In the pre-HCV era, plasmapheresis and immunosuppressants were the main treatments. At present, the therapy for HCV utilises pegylated interferons, ribavirin and amantadin according to current guidelines. The efficacy of the anti-viral treatments is sometimes increased by the combination of immunosuppressants and plasmapheresis. Higher doses, prolonged and combined treatments can be useful in the case of severe lesions or "hard-to-treat" HCV infections.
The first evidence of interferon (IFN) efficacy goes back to 1987: Bonomo et aI. showed a good response in 77% of the patients treated with IFNalfa (3 MU/die for 3 months) (53) . Different randomised controlled studies with different therapeutic schedules showed that interferon was able to alleviate the symptoms ofMC (54) (55) (56) and monoclonal B-cell proliferation (57) . However, IFN can enhance autoimmune diseases (58) ; autoimmune screening should therefore precede IFN. IFN is efficacious in MC associated with B hepatitis in the presence ofHBe-minus genotypes, too (59) . It acts by the inhibition of the viral replication. Cryocrit reduction follows the reduction of ALT, AST and viraemia (11) . There is a reduced formation of immunocomplexes, and an improvement of reticulo-endothelial hepatic and T-cellular function (11) . Prednisolone, like all steroids, should be avoided in the case of HCV infection or other viral infections, as it favours replication. Recent studies .show that the combined therapy ofIFN with ribavirin (60,61) also improves the cryoglobulinaemic syndrome (62) (63) (64) . There are no data, on the other hand, on the long term effects of the pegylated IFN on cryoglobulinaemia. The use ofIFN in some particular clinical pictures, such as neuropathy, nephropathy and ulcers, is controversial because of its anti-angiogenic activity that can delay the healing of the ischemic lesions (11, 65, 68) . Steroids improve the renal function and reduce proteinuria but do not affect the progression rate of the disease (11, (66) (67) . Plasmapheresis is indicated in the case of symptomatic and resistant disease, but only makes it possible to control the symptoms. (11) . In the absence of HCV infection, IFN does not represent the first-choice treatment because it can induce autoimmunity and cryoglobulinaemic vasculitis (63) . In perspective, Rituximab, a monoclonal anti-body against CD20 shows some efficacy in immunocytomas (11) .
